The European Commission approved Eli Lilly and Boehringer Ingelheim's combination therapy Jentadueto (linagliptin/metformin) for patients with type 2 diabetes, the companies reported Wednesday.
Specifically, the twice-daily product has been authorised for use alongside diet and exercise to improve glycaemic control in adults with type 2 diabetes who are inadequately controlled on their maximal tolerated dose of metformin alone, metformin and a sulphonylurea, or those already being treated with the combination of the DPP-4 inhibitor Tradjenta (linagliptin) and metformin. The therapy, which may also be used with a sulphonylurea, was cleared by the FDA in January.
The drugmakers noted that in clinical studies, patients with inadequate glycaemic control who took the highest dose of Jentadueto experienced placebo-corrected mean reductions in HbA1c levels of -1.7 percent.
Eli Lilly and Boehringer Ingelheim entered an agreement in 2011 to jointly develop and market a number of diabetes compounds, including Tradjenta.
To read more Top Story articles, click here.